Ascendis Pharma A/S
ASND163.350USD
-0.800-0.49%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
9.91BCap. mercado
PérdidaP/E TTM
Más Datos de Ascendis Pharma A/S Compañía
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Información de la empresa
Código de la empresaASND
Nombre de la empresaAscendis Pharma A/S
Fecha de salida a bolsaJan 28, 2015
Fundada en2006
Director ejecutivoMr. Jan Moller Mikkelsen
Número de empleados- -
Tipo de seguridadDepository Receipt
Fin del año fiscalJan 28
DirecciónTuborg Boulevard 12
CiudadHELLERUP
Bolsa de valoresNASDAQ Global Select Consolidated
PaísDenmark
Código postal2900
Teléfono4570222244
Sitio Webhttps://ascendispharma.dk/
Código de la empresaASND
Fecha de salida a bolsaJan 28, 2015
Fundada en2006
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael Wolff Jensen
Mr. Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Executive Vice President, Chief Legal Officer, Member of the Executive Board
5.76K
+198.45%
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
1.86K
+100.43%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
1.59K
+78.59%
Ms. Lisa Bright
Ms. Lisa Bright
Independent Director
Independent Director
1.09K
+178.01%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.09K
+178.01%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
364.00
--
Mr. Mads Bodenhoff
Mr. Mads Bodenhoff
Senior Vice President, Head of Finance and Principal Accounting Officer
Senior Vice President, Head of Finance and Principal Accounting Officer
193.00
--
Mr. Donovan (Jay) Wu
Mr. Donovan (Jay) Wu
Executive Vice President, U.S. President
Executive Vice President, U.S. President
--
--
Dr. Aimee Shu,, M.D.
Dr. Aimee Shu,, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Mr. William Carl (Bill) Fairey, Jr.
Mr. William Carl (Bill) Fairey, Jr.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael Wolff Jensen
Mr. Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Executive Vice President, Chief Legal Officer, Member of the Executive Board
5.76K
+198.45%
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
1.86K
+100.43%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
1.59K
+78.59%
Ms. Lisa Bright
Ms. Lisa Bright
Independent Director
Independent Director
1.09K
+178.01%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.09K
+178.01%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
364.00
--
Desglose de ingresos
Divisa: EURHora de actualización: dom., 6 de abr
Divisa: EURHora de actualización: dom., 6 de abr
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por negocioEUR
Nombre
Ganancia
Proporción
Commercial sale of products
55.71M
96.33%
Rendering of services
1.27M
2.20%
License
851.00K
1.47%
Sale of clinical supply
0.00
0.00%
Por regiónEUR
Nombre
Ganancia
Proporción
North America
48.76M
84.31%
Europe
8.15M
14.09%
Asia
924.00K
1.60%
Rest of world
924.00K
1.60%
Por negocio
Por región
Por negocioEUR
Nombre
Ganancia
Proporción
Commercial sale of products
55.71M
96.33%
Rendering of services
1.27M
2.20%
License
851.00K
1.47%
Sale of clinical supply
0.00
0.00%
Accionista
Hora de actualización: sáb., 26 de abr
Hora de actualización: sáb., 26 de abr
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
RA Capital Management, LP
16.66%
Westfield Capital Management Company, L.P.
9.11%
Avoro Capital Advisors LLC
8.41%
Artisan Partners Limited Partnership
7.33%
Janus Henderson Investors
7.22%
Other
51.27%
Estadísticas de accionistas
Accionista
Proporción
RA Capital Management, LP
16.66%
Westfield Capital Management Company, L.P.
9.11%
Avoro Capital Advisors LLC
8.41%
Artisan Partners Limited Partnership
7.33%
Janus Henderson Investors
7.22%
Other
51.27%
Tipo
Accionista
Proporción
Investment Advisor/Hedge Fund
42.21%
Investment Advisor
39.31%
Hedge Fund
25.01%
Research Firm
2.54%
Individual Investor
0.78%
Family Office
0.44%
Family Office
0.44%
Family Office
0.44%
Venture Capital
0.38%
Participación institucional
Hora de actualización: lun., 20 de ene
Hora de actualización: lun., 20 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
473
67.43M
111.11%
-2.45M
2024Q4
488
67.37M
111.00%
-7.76M
2024Q3
475
65.25M
107.66%
-6.23M
2024Q2
459
63.44M
108.94%
-9.21M
2024Q1
453
63.54M
109.13%
-8.68M
2023Q4
430
62.90M
109.00%
-9.55M
2023Q3
414
62.85M
109.61%
-11.90M
2023Q2
426
63.03M
109.93%
-13.27M
2023Q1
427
63.10M
110.08%
-9.14M
2022Q4
426
67.66M
118.40%
-4.66M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
RA Capital Management, LP
10.11M
16.66%
+402.32K
+4.14%
Dec 31, 2024
Westfield Capital Management Company, L.P.
5.53M
9.11%
+394.47K
+7.68%
Dec 31, 2024
Avoro Capital Advisors LLC
5.10M
8.41%
+114.17K
+2.29%
Dec 31, 2024
Artisan Partners Limited Partnership
4.45M
7.33%
+39.31K
+0.89%
Dec 31, 2024
Janus Henderson Investors
4.38M
7.22%
+193.69K
+4.63%
Dec 31, 2024
Fidelity Management & Research Company LLC
4.36M
7.18%
-196.51K
-4.32%
Dec 31, 2024
Capital International Investors
2.86M
4.72%
+753.86K
+35.74%
Dec 31, 2024
T. Rowe Price Investment Management, Inc.
2.73M
4.49%
+960.50K
+54.42%
Dec 31, 2024
T. Rowe Price Associates, Inc.
2.28M
3.76%
+162.08K
+7.64%
Dec 31, 2024
MFS Investment Management
1.86M
3.07%
-415.00
-0.02%
Dec 31, 2024
Ver más
ETFs relacionados
Hora de actualización: dom., 6 de abr
Hora de actualización: dom., 6 de abr
Nombre
Proporción
Harbor Health Care ETF
16.1%
Virtus LifeSci Biotech Products ETF
1.93%
BNY Mellon Innovators ETF
1.85%
Tema Cardiovascular and Metabolic ETF
1.43%
American Century Focused Dynamic Growth ETF
1.43%
ProShares Ultra Nasdaq Biotechnology
0.94%
Invesco Nasdaq Biotechnology ETF
0.9%
JPMorgan Healthcare Leaders ETF
0.66%
iShares Biotechnology ETF
0.61%
Main Thematic Innovation ETF
0.61%
Ver más
Harbor Health Care ETF
Proporción16.1%
Virtus LifeSci Biotech Products ETF
Proporción1.93%
BNY Mellon Innovators ETF
Proporción1.85%
Tema Cardiovascular and Metabolic ETF
Proporción1.43%
American Century Focused Dynamic Growth ETF
Proporción1.43%
ProShares Ultra Nasdaq Biotechnology
Proporción0.94%
Invesco Nasdaq Biotechnology ETF
Proporción0.9%
JPMorgan Healthcare Leaders ETF
Proporción0.66%
iShares Biotechnology ETF
Proporción0.61%
Main Thematic Innovation ETF
Proporción0.61%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos